61 results
424B5
RVPH
Reviva Pharmaceuticals Holdings Inc.
17 Nov 23
Prospectus supplement for primary offering
4:03pm
regarding executive compensation in our periodic reports and proxy statements.
Our eligibility to qualify as an emerging growth company will end … -on-frequency and say-on-golden parachute voting requirements and (iii) reduced disclosure obligations regarding executive compensation in our periodic
424B3
RVPH
Reviva Pharmaceuticals Holdings Inc.
5 Apr 23
Prospectus supplement
5:10pm
regarding executive compensation in our periodic reports and proxy statements.
In addition, the JOBS Act provides that an emerging growth company can take
POS AM
rzj29i2xc7
30 Mar 23
Prospectus update (post-effective amendment)
8:06am
424B4
y0jx7
18 Oct 22
Prospectus supplement with pricing info
7:01am
424B5
5kd0fdk
7 Sep 22
Prospectus supplement for primary offering
4:17pm
424B3
6mw4l zrt4i1axkdvllc
23 Mar 22
Prospectus supplement
4:15pm
424B3
i2ftmyk
23 Mar 22
Prospectus supplement
4:15pm
POS AM
vn6ikfh xugr6xrm
18 Mar 22
Prospectus update (post-effective amendment)
5:01pm
POS AM
6vouf2n94t eclhxkaw
18 Mar 22
Prospectus update (post-effective amendment)
5:00pm
424B3
sxoh6l9od571i930ae9c
2 Feb 22
Prospectus supplement
4:57pm
424B3
2pbui2fi92ofr
2 Feb 22
Prospectus supplement
4:52pm
S-3
d9ur 4wk0k
26 Jan 22
Shelf registration
4:15pm